Exelixis Inc (EXEL.OQ) Quote| Reuters.com
Edition:
United States

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

7.69USD
24 Jun 2016
Change (% chg)

$-0.16 (-2.04%)
Prev Close
$7.85
Open
$7.33
Day's High
$7.86
Day's Low
$7.21
Volume
2,252,680
Avg. Vol
940,808
52-wk High
$7.88
52-wk Low
$3.32

EXEL.OQ

Chart for EXEL.OQ

About

Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $1,759.01
Shares Outstanding(Mil.): 228.74
Dividend: --
Yield (%): --

Financials

  EXEL.OQ Industry Sector
P/E (TTM): -- 38.82 34.11
EPS (TTM): -0.90 -- --
ROI: -63.64 -5.72 14.23
ROE: -- -4.83 15.46

BRIEF-Exelixis, Ipsen post results from advanced renal cell carcinoma study

* Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX(tm) (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting

Jun 06 2016

BRIEF-Exelixis and Ipsen announce Phase 3 trial results of CABOMETYX

* Announced on Sunday Phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 06 2016

BRIEF-Ipsen SA says Exelixis Inc reported positive top-line results from Cabosun phase 2 trial of Cabozantinib

* reported positive top line results from Cabosun phase 2 trial of Cabozantinib in patients with untreated advanced renal cell carcinoma

May 23 2016

BRIEF-Exelixis reports Q1 loss per share $0.27

* Exelixis announces first quarter 2016 financial results and provides corporate update

May 04 2016

BRIEF-Ipsen partner Exelixis obtains FDA approval of CABOMETYX tablets

* Announces that its partner Exelixis obtained FDA approval of CABOMETYX (cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 26 2016

BRIEF-Exelixis gets FDA approval for Cabometyx tablets

* Exelixis announces FDA approval of Cabometyx(TM) (Cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy

Apr 25 2016

BRIEF-Exelixis and Ipsen enter into exclusive licensing agreement

* Exelixis and Ipsen enter into exclusive licensing agreement to commercialize and develop novel cancer therapy cabozantinib in regions outside the United States, Canada and Japan

Mar 01 2016

Competitors

  Price Chg
AstraZeneca plc (AZN.L) 4,031.50p +133.00
Pfizer Inc. (PFE.N) $33.97 -0.62
ArQule, Inc. (ARQL.OQ) $1.91 -0.01
GlaxoSmithKline plc (GSK.L) 1,482.00p +53.00
Algeta ASA (ALGETA.OL) -- --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Jefferson Research
$20.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.